arrow
L

Lucia Da Ros

centro di riferimento oncologico di aviano (cro) irccs
H指数:12
被引数:1,111

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prognostic impact of liquid biopsy (LB) biomarkers at relapse on second-line (2L) treatment (Tx) after progression to endocrine therapy (ET) in metastatic breast cancer (mBC): Ancillary analysis of the MAGNETIC.1 study

内分泌治疗(ET)进展后转移性乳腺癌(mBC)复发时液体活检(LB)生物标志物对二线(2L)治疗(Tx)的预后影响:MAGNETIC.1研究的附加分析

2024-09-010
PRE
Assessing interstitial lung disease (ILD) risk in metastatic breast cancer (MBC): A comprehensive meta and network analysis of antibody-drug conjugates (ADCs) compared to available treatment options beyond first-line (1L)

评估转移性乳腺癌(MBC)中特发性肺间质病变(ILD)风险:抗体偶联物(ADCs)与现有一线(1L)后治疗方案比较的全面Meta分析和网络分析

2024-09-010
PRE
Differential dynamics of fragmentomic and epigenetic circulating tumor DNA (ctDNA) features in first-line Palbociclib and Ribociclib treatment for Hormone Receptor (HR) positive, HER2 negative metastatic breast cancer (MBC)
2024-05-020
PRE
Unraveling the influence of progesterone receptor status on endocrine therapy sensitivity: insight from epigenetic and fragmentomics ctDNA profiling in estrogen receptor positive, HER2 negative metastatic breast cancer (MBC)
2024-05-020
PRE
Effect of L. crispatus M247 Administration on Pregnancy Outcomes in Women Undergoing IVF: A Controlled, Retrospective, Observational, and Open-Label Study
2023-11-175
OAAI
Patterns of time-to-progression intervals across clinical and liquid biopsy (LB) features in hormone receptor-positive (HR+) HER2-negative (HER2-) metastatic breast cancer (MBC) patients (pts) treated with first-line endocrine therapy (ET)
2023-10-010
OA
Clinical and biological predictors of lymph node involvement in patients with early breast cancer for adjuvant treatment personalization
2023-03-010
PRE
First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study

激素受体 (HR) 阳性HER2-negative转移性乳腺癌的一线和二线治疗策略: 一项真实世界研究

BREAST
IF7.9
2021-06-0121
OAAI
The SENECA study: Prognostic role of serum biomarkers in older patients with metastatic colorectal cancer
2020-11-019
PREAI
Plasma-Based Longitudinal Evaluation ofESR1Epigenetic Status in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer

基于血浆的激素受体阳性HER2-Negative转移性乳腺癌esr1表观遗传状态的纵向评估

2020-09-1821
OAAI
Predictors of relative dose intensity and early dose reduction in patients with metastatic breast cancer treated with palbociclib and endocrine therapy
2020-02-150
PRE